Two NIH Institutes Will Fund New Synchrotron Beamlines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

BETHESDA, Maryland-Two National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.

BETHESDA, Maryland—Two National Institutes of Health (NIH) units will jointly fund the design and construction of three new synchrotron beamlines as a way to increase x-ray crystallography studies of proteins.

The National Cancer Institute and the National Institute of General Medical Sciences expect the $23 million project to be fully operational in about 3 years. The three beamlines will be added to the new Advanced Proton Source at Argonne National Laboratory in Illinois.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content